Bristol Myers wins approval for KRAS drug Krazati in colorectal cancer

Bristol Myers Squibb won accelerated approval on Friday to take its KRAS inhibitor to colorectal cancer patients.

Krazati will now be available for use with …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

What Can Be Done for Severe RSV Cases in Adults?

Though there are now respiratory syncytial virus (RSV) vaccines approved by the FDA and recommended by the CDC for certain high-risk adults, what happens when

December 21, 2024

Bluebird snags more outcomes-based coverage for its $3M+ sickle cell gene therapy

A second outcomes-based agreement with an unidentified payer is now in the books for bluebird bio’s new $3.1 million sickle cell gene therapy, the company

January 5, 2024

Two type 1 diabetes patients now freed from insulin shots with cell therapy, Vertex reports

Vertex Pharmaceuticals said Friday that, over a year after receiving the company’s stem-cell therapy, two type 1 diabetes patients no longer need to take insulin

June 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.